OncLive TV

Dr Galsky on the Significance of the FDA Approval of Perioperative Durvalumab Plus Gemcitabine/Cisplatin for MIBC

March 28th 2025

Matthew Galsky, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy for patients with muscle-invasive bladder cancer.

Dr Ayoub on an AI Model to Enhance Interpretability of Morphologic Heterogeneity in Glioblastoma

March 28th 2025

Georges Ayoub, MD, MS, discusses how a supervised deep-learning model trained with expert-labeled data seeks to improve interpretability and diagnostic precision in glioblastoma morphological analysis.

Dr Teng on the Implications of Data From the CARES-005 Trial of TACE Plus Camrelizumab/Rivoceranib in HCC

March 28th 2025

Gao-Jun Teng, MD, contextualizes efficacy data with TACE plus camrelizumab and rivoceranib in HCC from the phase 2 CARES-005 trial.

Dr Chan on the FDA Approval of Cabozantinib for Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

March 28th 2025

Jennifer Chan, MD, MPH, discusses the FDA approval of cabozantinib for previously treated, advanced well-differentiated (extra) pancreatic neuroendocrine tumors.

Dr Alawadhi on the Link Between Obesity/Overweight and Breast Cancer Outcomes

March 28th 2025

Aydah Alawadhi, MBBS, discusses the effect of obesity and overweight status on patient outcomes across subgroups of early-stage breast cancer.

Dr Dholaria on Future Research Directions With P-BCMA-ALLO1 in R/R Multiple Myeloma

March 28th 2025

Bhagirathbhai Dholaria, MBBS, discusses future directions for research with P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma.

Dr Maughan on the Need for Consensus on Treatment Intensification in mHSPC

March 27th 2025

Benjamin L. Maughan, MD, PharmD, discusses the need for improved update of treatment intensification in metastatic hormone-sensitive prostate cancer.

Dr Morgans on Standardizing the Management of Bone/Cardiac Health With Systemic Therapy in Prostate Cancer

March 27th 2025

Alicia Morgans, MD, MPH, discusses the importance of managing bone and cardiac health in patients with prostate cancer receiving systemic therapy.

Dr Park on Individualized First-Line Bladder Cancer Management Options

March 27th 2025

Chandler Park, MD, discusses key factors that facilitate decisions between the available frontline treatment regimens for patients with bladder cancer.

Dr Eskander on the Potential Clinical Benefit of Nivolumab in dMMR Endometrial Cancer

March 27th 2025

Ramez N. Eskander, MD, discusses the key efficacy findings and future implications of the NIVEC trial of nivolumab in resectable dMMR endometrial cancer.

Dr Rimm on How FDA-Approved IHC Tests Pose Reproducibility Challenges in Breast Cancer

March 27th 2025

David Rimm, MD, PhD, discusses how FDA-approved IHC assays may lack reproducibility in real-world settings in breast cancer.

Dr Bowman on the Role of Kidney Cancer Awareness in Earlier Detection and Improved Patient Outcomes

March 27th 2025

Alex Bowman, MD, discusses the need for early symptom recognition, genetic risk evaluation, and research support to improve RCC detection and outcomes.

Dr Mirza on Long-Term Response Data for Dostarlimab Plus Chemo in Advanced Endometrial Cancer

March 26th 2025

Dr Sonpavde on the Ongoing Investigation of V940 Plus Pembrolizumab in High-Risk MIBC

March 26th 2025

Guru P. Sonpavde, MD, discusses the INTerpath-005 study evaluating adjuvant V940 plus pembrolizumab in resected high-risk MIBC.

Dr Paredes on the Association Between Fiber Intake and Improved Survival With Reduced GI aGVHD After Allo-HCT

March 26th 2025

Jenny Paredes, PhD, discusses how increased dietary fiber was associated with improved 24-month survival and reduced lower GI aGVHD in allo-HCT recipients.

Dr Wang on the Role of Menin Inhibitors in Genetically Defined AML Subtypes

March 26th 2025

Eunice S. Wang, MD, discusses the role of menin inhibitors like revumenib in AML with KMT2A rearrangements or NPM1 mutations.

Dr Tyson on Factors Influencing the Selection of Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

March 25th 2025

Mark D. Tyson, II, MD, MPH, discusses challenges choosing between nadofaragene firadenovec, nogapendekin alfa, and pembrolizumab in BCG-unresponsive NMIBC.

Dr Morgans on PSA Doubling Time and Treatment Decisions in Biochemically Recurrent nmHSPC

March 25th 2025

Alicia Morgans, MD, MPH, discusses how a lack of PSA doubling time documentation may lead to undertreatment in high-risk BCR prostate cancer.

Dr Lang on Real-World Safety Data for Perioperative Pembrolizumab in Early TNBC

March 25th 2025

Julie Lang, MD, discusses real-world safety data from for the KEYNOTE-522 regimen in early triple-negative breast cancer.

Dr Krishnan on T-Cell Therapies and Novel Targets Reshaping the Myeloma Treatment Landscape

March 25th 2025

Amrita Krishnan, MD, highlights key innovations in multiple myeloma, including GPRC5D-targeted agents and evolving strategies in T-cell–directed therapy.